OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

GENMAB AS DK 1/  DK0010272202  /

Lang & Schwarz
9/16/2024  10:58:15 PM Chg. -4.00 Volume Bid10:58:15 PM Ask10:58:15 PM Market Capitalization Dividend Y. P/E Ratio
237.30EUR -1.66% -
Turnover: -		 237.30Bid Size: - 240.50Ask Size: - 15.73 bill.EUR - -
GlobeNewswire 8/19 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 8/8 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 8/8 Genmab Updates 2024 Financial Guidance
GlobeNewswire 8/5 Genmab Takes Full Control of Acasunlimab Development Program
GlobeNewswire 6/28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 5/21 Genmab Completes Acquisition of ProfoundBio
GlobeNewswire 5/2 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 4/30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 4/3 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 2/14 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 2/14 Genmab Publishes 2023 Annual Report
GlobeNewswire 11/9/2023 Major Shareholder Announcement
GlobeNewswire 11/8/2023 Major Shareholder Announcement
GlobeNewswire 11/7/2023 Genmab Announces Financial Results for the First Nine Months of 2023
GlobeNewswire 10/17/2023 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire 9/25/2023 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire 9/4/2023 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire 2/24/2022 Notice to Convene the Annual General Meeting of Genmab A/S
GlobeNewswire 2/16/2022 Genmab Publishes 2021 Annual Report
GlobeNewswire 1/25/2022 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
GlobeNewswire 11/10/2021 Genmab Announces Financial Results for the First Nine Months of 2021
GlobeNewswire 11/4/2021 Genmab Improves its 2021 Financial Guidance
GlobeNewswire 10/19/2021 Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire 9/21/2021 Capital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswire 9/20/2021 Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...